Business / Finance

RSS

DJOFL second quarter net sales increase 14.5% to $277.8 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC, for the second quarter of fiscal 2011, ended July 2, 2011.

16 Aug 2011

Patient Safety Technologies second quarter total revenue decreases to $2.6 million

Patient Safety Technologies, Inc. today announced financial results for its second quarter of 2011 ended June 30, 2011.

16 Aug 2011

Concord Medical second quarter total net revenues increase 24.5% to $19.2 million

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced higher revenues, net income, and earnings per ADS for its unaudited consolidated financial results for the second quarter ended June 30, 2011 compared with the second quarter ended June 30, 2010.

16 Aug 2011

Stellacure to open umbilical cord blood stem cell company in Jordan

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that Stellacure, GmbH, its stem cell company headquartered in Hamburg, Germany, has entered into an agreement with a licensee in Jordan to open an umbilical cord blood stem cell company in that Middle East nation.

16 Aug 2011

China Medical first fiscal quarter net revenues increase 27.4% to US$36.7 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, announced its unaudited financial results for the first fiscal quarter ended June 30, 2011 today.

16 Aug 2011

China Shenghuo second quarter total revenue increases 58% to $10.9 million

China Shenghuo Pharmaceutical Holdings, Inc., today reported unaudited financial results for the second quarter ended June 30, 2011.

16 Aug 2011

Akela total consolidated revenues increase to $7.3M for six months ended June 30, 2011

Akela Pharma, Inc. and PharmaForm, a leading specialty contract service provider in the area of pharmaceutical dosage form development and manufacturing, today announced its financial results for the three and six months and year ended June 30, 2011.

16 Aug 2011

Medgenics second quarter net loss increases to $2.32 million

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for the three and six months ended June 30, 2011.

12 Aug 2011

L3I announces new Outcome Based Partnership hybrid business model

Level 3 Inspection has announced an Outcome Based Partnership hybrid business model based on vested interest partnership and proven time-to-market savings.

12 Aug 2011

Misonix adds MD Solutions to distribution network in Asia and the South Pacific

Misonix, Inc., a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide has entered into a new three-year exclusive distribution agreement with MD Solutions Australasia Pty. Ltd., based in Newport, Victoria, Australia.

12 Aug 2011

Boston health organizations plan merger

Partners HealthCare and Neighborhood Health Plan sign letter of intent for merger. In other hospital issues, Parkland Hospital In Dallas is in danger of losing Medicare accreditation and Conn. regulators are criticized.

12 Aug 2011

5N Plus closes new $250M senior secured multi-currency revolving credit facility

5N Plus Inc. announced today the closing of a new $250 million senior secured multi-currency revolving credit facility to replace its existing $50 million two-year senior secured revolving facility with National Bank of Canada.

12 Aug 2011

Thorne acquires global rights to Q-Cell, an advanced formulation Coenzyme Q10

Thorne Research, Inc., a leader in developing and manufacturing pure, high quality nutritional supplements marketed through licensed healthcare practitioners, has acquired exclusive global rights to market Q-Cell, an advanced formulation Coenzyme Q10 (CoQ10) supplement formerly marketed under the brand name Q-Best.

12 Aug 2011

PLC Systems second quarter total revenues increase to $398,000

PLC Systems Inc., a company focused on innovative medical device technologies, today reported financial results for the three- and six month periods ended June 30, 2011. These results only include the company's RenalGuard® operations, since PLC completed the sale of its transmyocardial revascularization (TMR) business to Novadaq Corp. during the first quarter of 2011.

12 Aug 2011

Hooper Holmes second quarter consolidated revenues decline 7% to $37.9 million

Hooper Holmes today announced financial results for the quarter ended June 30, 2011.

12 Aug 2011

Galectin second quarter net loss increases to $3.9 million

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the second quarter and first six months, ended June 30, 2011.

12 Aug 2011

Interleukin Genetics second quarter total revenue increases to $0.8 million

Interleukin Genetics, Inc. today announced financial and operational results for the second quarter ended June 30, 2011.

12 Aug 2011

Echo net loss for first half 2011 increases to $6.5 million

Echo Therapeutics, Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude SkinPrep System for transdermal drug delivery, today announced results for the period ended June 30, 2011.

12 Aug 2011

Bovie Medical second quarter revenues increase 16% to $6.8 million

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the second quarter and six months ended June 30, 2011.

12 Aug 2011

ShangPharma approves share repurchase program

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its Board of Directors has approved a share repurchase program.

12 Aug 2011